Multiple System Atrophy drug pipeline
1 compound from 1 company is in active clinical development for multiple system atrophy.
1Compound
1Company
0Phase 3+
1Upcoming readout
1Trials recruiting
- Phase 2 1
Mechanisms: Small molecule (1)
Pipeline data compiled July 2026 · every fact sourced.
Upcoming readouts & recent results
Anticipated Phase 2 (TOPAS-MSA) topline in multiple system atrophy (primary endpoint: change from baseline in UMSARS at week 48) ↗
Compounds in development (1)
| Compound | Company | Phase | Status | Mechanism |
|---|---|---|---|---|
| EmrusolminOrphanFast Track | Teva Pharmaceutical Industries Ltd. | Phase 2 | Recruiting | Alpha-synuclein Modulator |
Trials recruiting now
1 registered interventional multiple system atrophy trial — none recruiting at present. Browse all on ClinicalTrials.gov →
Frequently asked
- How many drugs are in development for multiple system atrophy?
- 1 compound from 1 company is in active clinical development for multiple system atrophy.
- What are the next multiple system atrophy trial readouts?
- Upcoming catalysts include Emrusolmin (2H 2027).